Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory fi
After more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down as CEO, to be replaced by biopharma industry veteran Tony Kingsley.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.